Abstract
The cytokine, tumor necrosis factor alpha (TNFα), has been implicated in many aspects of immune system development, immune response regulation, and T cell-mediated tissue injury. TNFα plays a less well-defined role in the pathogenesis of the idiopathic inflammatory myopathy (IIM) group of disorders, and has been considered a potential therapeutic target. Observational studies of TNFα-blockade in (mostly refractory) IIM have yielded inconsistent beneficial results so that administration of these biological agents is presently deemed an unreliable alternative treatment strategy. Moreover, anti-TNFα therapy has the rare potential to trigger myositis in patients with rheumatoid arthritis, hinting at a pre-existing “overlap disorder”. The full potential of TNFα-antagonism will be realized only if randomized controlled trials ascertain appropriate treatment regimens and identify patient subgroups most likely to benefit from such therapy.
Similar content being viewed by others
References
Lepidi H, Frances V, Figarella-Branger D, Bartoli C, Machado-Baeta A, Pellissier JF (1998) Local expression of cytokines in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 24:73–79
Figarella-Branger D, Civate M, Bartoli C, Pellissier JF (2003) Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies. Muscle Nerve 28:659–682
Salomonsson S, Lundberg IE (2006) Cytokines in idiopathic inflammatory myopathies. Autoimmunity 39:177–190
Cope A, Ettinger R, McDevitt H (1997) The role of TNF-α and related cytokines in the development and function of the autoreactive T-cell repertoire. Res Immunol 148:307–312
Kollias G, Douni E, Kassiotis G, Kontoyiannis D (1999) The role of tumor necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. Ann Rheum Dis 58(Suppl):32–39
Robinson WH, Genovese MC, Moreland LW (2001) Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 44:1977–1983
Goetz FW, Planas JV, Mackenzie S (2004) Tumor necrosis factors. Dev Comp Immunol 28:287–297
Idriss HT, Naismith J (2000) TNF alpha and the TNF receptor superfamily: structure–function relationship(s). Microsc Res Tech 50:184–195
MacEwan DJ (2002) TNF receptor subtype signaling: differences and cellular consequences. Cell Signal 14:477–492
Slowik MR, De Luca LG, Fiers W, Pober JS (1993) Tumor necrosis factor activates human endothelial cells through the p55 tumor necrosis receptor but the p75 receptor contributes to activation at low tumor necrosis factor concentration. Am J Pathol 143:1724–1730
Mackay F, Loetscher H, Stueber D, Gehr G, Lesslauer W (1993) Tumor necrosis factor alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55. J Exp Med 177:1277–1286
Barbara JA, Smith WB, Gamble JR, Van Ostade X, Vandenabeele P, Tavernier J, Fiers W, Vadas MA, Lopez AF (1994) Dissociation of TNF-alpha cytotoxic and proinflammatory activities by p55 receptor- and p75 receptor-selective TNF-alpha mutants. EMBO J 13:843–850
Holtmann MH, Neurath MF (2004) Differential TNF-signaling in chronic inflammatory disorders. Curr Mol Med 4:439–444
Mukai Y, Shibata H, Nakamura T, Abe Y, Nomura T, Taniai M, Ohta T, Ikemizu S, Nakagawa S, Tsunoda S, Kamada H, Yamagata Y, Tsusumi Y (2009) Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant. J Mol Biol 385:1221–1229
Hofmann C, Lorenz K, Braithwaite SS, Colca JR, Palazuk BJ, Hotamisligil GS, Spiegelman BM (1994) Altered gene expression for tumor necrosis factor-alpha and its receptor during drug and dietary modulation of insulin resistance. Endocrinology 134:264–270
Chabaud M, Fossiez F, Taupin JL, Miossec P (1998) Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 161:409–414
Nagaraju K, Raben N, Merritt G, Loeffler L, Kirk K, Plotz P (1998) A variety of cytokines and immunologically relevant surface molecules are expressed by normal human skeletal muscle cells under proinflammatory stimuli. Clin Exp Immunol 113:407–414
Seko Y, Matsuda H, Kato K, Hashimoto Y, Yagita H, Okumura K, Yazaki Y (1993) Expression of intercellular adhesion molecule-1 in murine hearts with acute myocarditis caused by coxsackie virus B3. J Clin Invest 91:1327–1336
Michaelis D, Goebels N, Hohlfeld R (1993) Constitutive and cytokine-induced expression of human leukocyte antigens and cell adhesion molecules by human myotubes. Am J Pathol 143:1142–1149
De Bleecker JL, Engel AG (1994) Expression of cell adhesion molecules in inflammatory myopathies and Duchenne dystrophy. J Neuropathol Exp Neurol 53:369–376
Moser B, Wolf M, Waltz A, Loetscher P (2004) Chemokines: multiple levels of leukocyte migration control. Trends Immunol 25:75–84
ENBREL (etanercept) (2007) Current prescribing information. In: Physicians’ desk reference. Thompson, Montvale, pp 584–591
HUMIRA (adalimumab) (2007) Current prescribing information. In: Physicians’ desk reference. Thompson, Montvale, pp 466–471
Page G, Chevrel G, Miossec P (2004) Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: interaction with chemokines and Th1 cytokine-producing cells. Arthritis Rheum 50:199–208
Scheurich P, Thoma B, Ucer U, Pfizenmaier K (1987) Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses. J Immunol 138:1786–1790
Cope AP, Liblau RS, Yang XD, Congia M, Laudanna C, Schreiber RD, Probert L, Kollias G, McDevitt HO (1997) Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med 185:1573–1584
Greenberg SA (2009) Inflammatory myopathies: disease mechanisms. Curr Opin Neurol 22:516–523
Limaye VS, Blimbergs P, Roberts-Thomson PJ (2009) Idiopathic inflammatory myopathies. Intern Med J 39:179–190
Krathen MS, Fiorentino D, Werth VP (2008) Dermatomyositis. Curr Dir Autoimmun 10:313–332
Khanna S, Reed AM (2010) Immuno pathogenesis of juvenile dermatomyositis. Muscle Nerve 41:581–592
Mammen AL (2010) Dermatomyositis and polymyositis: clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci 1184:134–153
Amato AA, Barohn RJ (2009) Inclusion body myositis: old and new concepts. J Neurol Neurosurg Psychiatry 80:1186–1193
Greenberg SA (2010) Theories of the pathogenesis of inclusion body myositis. Curr Rheumatol Rep 12:221–228
Shimizu T, Tomita Y, Son K, Nishinarita S, Sawada S, Horie T (2000) Elevation of serum soluble tumor necrosis factor receptors in patients with polymyositis and dermatomyositis. Clin Rheumatol 19:352–359
Kuru S, Inukai A, Liang Y, Doyu M, Takano A, Sobue G (2000) Tumor necrosis factor-alpha expression in muscles of polymyositis and dermatomyositis. Acta Neuropathol 99:585–588
Kuru S, Inukai A, Kato T, Liang Y, Kimura S, Sobue G (2003) Expression of tumor necrosis factor-alpha in regenerating muscle fibers in inflammatory and non-inflammatory myopathies. Acta Neuropathol (Berl) 105:217–224
De Bleecker JL, Meire VI, Declerq W, Van Aken EH (1999) Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies. Neuromuscul Disord 9:239–246
Peterson JM, Feeback KD, Baas JH, Pizza FX (2006) Tumor necrosis factor-alpha promotes the accumulation of neutrophils and macrophages in skeletal muscle. J Appl Physiol 101:1394–1399
Schmidt J, Barthel K, Wrede A, Salajegheh M, Bahr M, Dalakas MC (2008) Interrelation of inflammation and APP in sIBM: IL-1β induces accumulation of β-amyloid in skeletal muscle. Brain 131:1228–1240
Gallucci S, Provenzano C, Mazzarelli P, Scuderi F, Bartoccioni E (1998) Myoblasts produce IL-6 in response to inflammatory stimuli. Int Immunol 10:267–273
Chen SE, Jin B, Li YP (2007) TNF-alpha regulates myogenesis and muscle regeneration by activating p38 MAPK. Am J Physiol Cell Physiol 292:1660–1671
Langen RC, van der Velden JL, Schols AM, Kelders MC, Wouters EF, Janssen-Heininger YM (2004) Tumor necrosis factor-alpha inhibits myogenic differentiation through MyoD protein destabilization. FASEB J 18:227–237
Lecker SH, Solomon V, Mitch WE, Goldberg AL (1999) Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. J Nutr 129(Suppl 1):227–237
Dinarello CA (1996) Biologic basis for interleukin-1 in disease. Blood 87:2095–2147
Tracey KJ, Lowry SF, Beutler B, Cerami A, Albert JD, Shires GT (1986) Cachectin/tumor necrosis factor mediates changes of skeletal muscle plasma membrane potential. J Exp Med 164:1368–1373
Lee MD, Zentella A, Vine W, Pekala PH, Cerami A (1987) Effect of endotoxin-induced monokines on glucose metabolism in the muscle cell line L6. Proc Natl Acad Sci USA 84:2590–2594
Flores EA, Bistrian BR, Pomposelli JJ, Dinarello CA, Blackburn GL, Istfan NW (1989) Infusion of tumor necrosis factor/cachectin promotes muscle catabolism in the rat. A synergistic effect with interleukin 1. J Clin Invest 83:1614–1622
Goodman MN (1991) Tumor necrosis factor induces skeletal muscle protein breakdown in rats. Am J Physiol 260:E727–E730
Garcia-Martinez C, Agell N, Llovera M, Lopez-Soriano FJ, Argiles JM (1993) Tumor necrosis factor-alpha increases the ubiquitinization of rat skeletal muscle proteins. FEBS Lett 323:211–214
Reid MB, Li YP (2001) Tumor necrosis factor-alpha and muscle wasting: a cellular perspective. Respir Res 2:269–271
Reid MB, Lannergren J, Westerblad H (2002) Respiratory and limb muscle weakness induced by tumor necrosis factor alpha: involvement of muscle myofilaments. Am J Respir Crit Care Med 166:479–484
Pachman LM, Liotta-Davis MR, Hong DK, Kinsella TR, Mendez EP, Kinder JM, Chen EH (2000) TNFalpha-308 allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum 43:2368–2377
Pachman LM, Fedczyna TO, Lechman TS, Lutz J (2001) Juvenile dermatomyositis: the association of the TNF alpha-308A allele and disease chronicity. Curr Rheumatol Rep 3:379–386
Werth VP, Callen JP, Ang G, Sullivan KE (2002) Associations of tumor necrosis factor alpha and HLA polymorphisms with adult dermatomyositis: implications for a unique pathogenesis. J Invest Dermatol 119:617–620
Hassan AB, Nikitina-Zake L, Sanjeevi CB, Lundberg IE, Padyukov L (2004) Association of the proinflammatory haplotype(MICA5.1/TNF2/TNFα2/DRB1*03) with polymyositis and dermatomyositis. Arthritis Rheum 50:1013–1015
Hassan AB, Fathi M, Dastmalchi M, Lundberg IE, Padyukov L (2006) Genetically determined imbalance between serum levels of tumour necrosis factor (TNF) and interleukin (IL)-10 is associated with anti-Jo-1 and anti-Ro52 autoantibodies in patients with poly- and dermatomyositis. J Autoimmun 27:62–68
Bradley JR (2008) TNF-mediated inflammatory disease. J Pathol 214:149–160
REMICADE (infliximab) (2007) Current prescribing information. In: Physicians desk reference. Thompson, Montvale, pp 971–979
Efthimiou P (2006) Tumor necrosis factor-alpha in inflammatory myopathies: pathophysiological and therapeutic implications. Semin Arthritis Rheum 36:168–172
Hengstman G, van den Hoogen F, van Engelen B, Barrera P, Netea M (2000) Anti-TNF-blockade with infliximab (Remicade®) in polymyositis and dermatomyositis. Arthritis Rheum 43:S193
Saadeh CK (2000) Etanercept is effective in the treatment of polymyositis/dermatomyositis which is refractive to conventional therapy including steroid and other disease modifying agents. Arthritis Rheum 43:S193
Singh R, Cuchacovich R, Huang W, Espinoza LR (2001) Inclusion body myositis unresponsive to etanercept. J Clin Rheumatol 7:279–280
Roddy E, Courtney PA, Morris A (2002) Non-Hodgkin’s lymphoma in a patient with refractory dermatomyositis which had been treated with infliximab. Rheumatology 41:1194–1195
Sprott H, Glatzel M, Michel BA (2004) Treatment of myositis with etanercept (Enbrel®), a recombinant human soluble fusion protein of TNF-α type II receptor and IgG1. Rheumatology 43:524–526
Laboiche I, Liozon E, Weschler B, Loustaud-Ratti P, Soria P, Vidal E (2004) Refractory polymyositis responding to infliximab: extended follow-up. Rheumatology 43:532–533
Uhtman I, El-Sayad J (2004) Refractory polymyositis responding to infliximab. Rheumatology 43:1198–1199
Korkmaz C, Temiz G, Çetinbas F, Büyükkidan B (2004) Case report: successful treatment of alveolar hypoventilation due to dermatomyositis with anti-tumour necrosis factor-alpha. Rheumatology 43:938–939
Selva-O’Callaghan A, Martînez-Costa X, Solans-Laque R, Mauri M, Capdevila JA, Vilardell-Tarrés M (2004) Refractory adult dermatomyositis with pneumatosis cystoides intestinalis treated with infliximab. Rheumatology 43:1197–1198
Marie I, Heliot P, Roussel F, Hervé F, Muir JF, Levesque H (2005) Fatal Mycobacterium peregrinum pneumonia in refractory polymyositis treated with infliximab. Rheumatology 44:1202–1203
Anandacoomarasamy A, Howe G, Manolios N (2005) Advanced refractory polymyositis responding to infliximab. Rheumatology 44:562–563
Dold S, Justiniano ME, Marquez J, Espinoza LR (2007) Treatment of early and refractory dermatomyositis with infliximab: a report of 2 cases. Clin Rheumatol 26:1186–1188
Wendling D, Prati C, Ornetti P, Toussirot E, Streit G (2007) Anti TNF-alpha treatment of a refractory polymyositis. Rev Med Interne 28:194–195
Choi KH, Yoo WH (2009) Necrotizing fasciitis in a patient treated with etanercept for dermatomyositis. Rheumatol Int 29:463–466
Hill CL, Zhang Y, Sigurgeirsson B, Pukkula E, Mellemkjaer L, Airio A, Evans SR, Felson DT (2001) Frequency of specific cancer types in dermatomyositis and polymyositis: a population based study. Lancet 357:96–100
Marie I, Hachulla E, Chérin P, Hellot MF, Herson S, Levesque H, Hatron PY (2005) Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum 53:155–165
Efthimiou P, Schwartzman S, Kagen LJ (2006) Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of 8 patients. Ann Rheum Dis 65:1233–1236
Iannone F, Scioscia C, Falappone PC, Covelli M, Lapadula G (2006) Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol 33:1802–1804
Riley P, McCann LJ, Maillard SM, Woo P, Murray KJ, Pilkington CA (2008) Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology 47:877–880
Vandenbroucke JP (2001) In defense of case reports and case series. Ann Intern Med 134:330–334
Noordzij M, Dekker FW, Zoccali C, Jager KJ (2009) Study design in clinical research. Nephron Clin Pract 113:c218–c221
Jenicek M (1999) Clinical case reporting in evidence-based medicine. Butterworths, Oxford, p 1999
Barohn RJ, Herbelin L, Kissel JT, King W, McVey AL, Saperstein DS, Mendell JR (2006) Pilot trial of etanercept in the treatment of inclusion-body myositis. Neurology 66(Suppl 1):S123–S124
Hengstman GJ, de Bleecker JL, Feist E, Vissing J, Denton CP, Manoussakis MN, Slott Jensen H, van Engelen BG, van den Hoogen FH (2008) Open-label trial of anti-TNF-α in dermatomyositis and polymyositis treated concomitantly with methotrexate. Eur Neurol 59:159–163
Hengstman GJ, van den Hoogen FH, Barrera P, Netea MG, Pieterse A, van de Putte LB, van Engelen BG (2003) Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol 50:10–15
Hengstman GJ, van den Hoogen FH, van Engelen BG (2004) Treatment of dermatomyositis and polymyositis with anti-tumor-necrosis factor-α: long-term follow-up. Eur Neurol 52:61–63
Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Helmers SB, Elvin K, Crow MK, Nennesmo I, Lundberg IE (2008) A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 67:1670–1677
Ramos-Casals M, Brito-Zeron P, Muñoz S, Soria N, Galiana D, Bertolaccini L, Cuadrado MJ, Khamashta MA (2007) Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86:242–251
Ramos-Casals M, Brito-Zeron P, Soto MJ, Cuadrado MJ, Khamashta MA (2008) Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 22:847–861
Borrås-Biasco J, Navarro-Ruiz A, Borrås C, Casterå E (2009) Adverse cutaneous reactions induced by TNF-alpha antagonist therapy. South Med J 102:1133–1140
Wetter DA, Davis MD (2009) Lupus-like syndrome attributable to anti-tumor necrosis factor therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc 84:979–984
Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, Khamashta MA, BIOGEAS Study Group (2010) Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 9:188–193
Mohan N, Edwards ET, Cupps TR, Oliviero PJ, Sandberg G, Crayton H, Richert JR, Siegel JN (2001) Demyelination occurring during anti-tumor necrosis factor α therapy for inflammatory arthritis. Arthritis Rheum 44:2862–2869
Tristano AG (2010) Neurological adverse events associated with anti-tumor necrosis factor alpha treatment. J Neurol 257:1421–1431
Stübgen JP (2008) Tumor necrosis factor-α antagonists and neuropathy. Muscle Nerve 37:281–292
Musial J, Undas A, Celinska-Lowenhoff M (2003) Polymyositis associated with infliximab treatment for rheumatoid arthritis. Rheumatology (Oxford) 42:1566–1568
Urata Y, Wakai Y, Kowatari K, Nitobe T, Mizushima Y (2006) Polymyositis associated with infliximab treatment for rheumatoid arthritis. Mod Rheumatol 16:410–411
Hall HA, Zimmermann B (2006) Evolution of dermatomyositis during therapy with a tumor necrosis factor α inhibitor. Arthritis Rheum 15:982–984
Liozon E, Outtara V, Loustaud-Ratti V, Vidal E (2007) Severe polymyositis and flare in autoimmunity following treatment with adalimumab in a patient with overlapping features of polyarthritis and scleroderma. Scand J Rheumatol 36:484–486
Vordenbaumen S, Neuen-Jacob E, Richter J, Schneider M (2010) Inclusion body myositis in a patient with long standing rheumatoid arthritis treated with anti-TNFα and rituximab. Clin Rheumatol 29:555–558
Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ (2004) The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology 126:19–31
Miller FW, Hess EV, Clauw DJ, Hertzman PA, Pincus T, Silver RM, Mayes MD, Varga J, Medsger TA Jr, Love LA (2000) Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis Rheum 43:243–249
Pitkeathly DA, Coomes EN (1966) Polymyositis in rheumatoid arthritis. Ann Rheum Dis 25:127–132
Targoff IN (2002) Idiopathic inflammatory myopathy: autoantibody update. Curr Rheum Rep 4:434–441
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stübgen, JP. Tumor necrosis factor-alpha as a potential therapeutic target in idiopathic inflammatory myopathies. J Neurol 258, 961–970 (2011). https://doi.org/10.1007/s00415-011-5907-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-011-5907-2